20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BridgeBio Oncology Therapeutics, Inc. (BBOT) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 88 employees. Its market capitalization is roughly $210 million. In the fiscal year ended 2025-12-31, BBOT reported $0M in revenue and ($134M) in net income.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — | — |
| Gross Profit | — | ($1M) | — | — | — | — |
| Gross Margin % | — | — | — | — | — | — |
| Operating Income (EBIT) | ($199M) | ($146M) | ($81M) | ($65M) | $0M | $0M |
| Operating Margin % | — | — | — | — | — | — |
| Net Income | ($182M) | ($134M) | ($74M) | ($65M) | $0M | $0M |
| Net Margin % | — | — | — | — | — | — |
| EBITDA | ($195M) | ($145M) | ($81M) | ($65M) | $0M | $0M |
| Earnings Per Share (EPS) | $-1,232.83 | $-4.30 | $-5,756.41 | $-3.16 | $-0.00 | $-0.00 |
| Shares Outstanding (M) | 0M | 31M | 0M | 20M | 20M | 20M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | — | — | — | — | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($60M) | ($46M) | ($43M) | ($49M) | ($30M) | ($23M) | ($22M) | ($20M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($56M) | ($42M) | ($39M) | ($45M) | ($28M) | ($22M) | ($20M) | ($17M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($56M) | ($46M) | ($43M) | ($49M) | ($30M) | ($23M) | ($22M) | ($20M) |
| Earnings Per Share (EPS) | $-705.20 | $-526.11 | $-0.49 | $-1.03 | $-566.46 | $-54.23 | $-1,075.56 | $-0.74 |
| Shares Outstanding (M) | 0M | 0M | 80M | 43M | 0M | 0M | 0M | 24M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($193M) | ($114M) | ($1M) | ($52M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($194M) | ($114M) | ($1M) | ($52M) |
| FCF Margin % | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($36M) | ($42M) | ($71M) | ($23M) | ($1M) | $0M | ($39M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($44M) | ($36M) | ($42M) | ($71M) | ($24M) | ($1M) | $0M | ($39M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Assets | $377M | $448M | $194M | $0M | $0M | $0M |
| Cash & Cash Equivalents | $54M | $374M | $2M | $0M | — | — |
| Total Liabilities | $54M | $37M | $6M | $0M | $0M | $0M |
| Total Debt (Short + Long-Term) | $1M | $1M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $323M | $411M | $189M | $0M | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BBOT viewer.
About TickerBase · Data methodology & sources · Privacy · Terms